Survival in children with acute lymphoblastic leukemia could be significantly influenced by their family’s socioeconomic status, a new study published in Pediatric Blood and Cancer has found.
Survival in children with acute lymphoblastic leukemia (ALL), the most common pediatric cancer (responsible for 75 to 80% of childhood leukemia), could be significantly influenced by their family’s socioeconomic status, a new study conducted by researchers at the Dana-Farber Cancer Institute has found.
Children between the ages of 1 and 18 years, who were treated for ALL on the Dana-Farber Cancer Institute ALL Consortium Protocols between 2000 and 2010, were included in a study published in Pediatric Blood and Cancer. The researchers used zip codes of the areas where the families resided as a surrogate for poverty level, with high-poverty areas defined as ones where 20% or more residents had income below the federal poverty level (annual income of less than or equal to $24,250 for a family of 4).
Rationalizing the hypothesis of their study, lead author Kira Bona, MD, MPH, a pediatric oncologist at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center said in a press release, “These children are getting the same best possible care at well-resourced institutions from highly trained clinicians, and we’re still seeing disparities. In trying to improve cure rates, we, as a field, have focused almost exclusively on biology. If we want to move forward, we also have to look at social determinants.”
Among the 575 children included in the study, overall rates of relapse were similar between the 2 groups being compared: high-poverty and low-poverty. However, 92% of children included in the lower economic strata group relapsed much earlier (less than 36 months following complete remission) compared with 48% of the remaining children. Further, residents of high-poverty areas had a 5-year overall survival (OS) of 85%, compared with 92% for those in low-poverty areas (P = .02). Statistical significance of the OS data, however, was lost after adjusting for immunophenotype, age, and white blood cell count. It is important to note that although OS was the same between the 2 groups, ALL that relapses early is harder to treat successfully, which underscores the significance of the study’s findings.
According to Bona, 20% of children live in poverty in the United States. “If we can devise successful interventions, that’s at least 20% of children with cancer whose outcomes we can potentially impact. Any 'moon shot' to cure cancer must include interventions that target socio-economic disparities in outcomes,” she added.
Future studies by these researchers will identify associations between disease outcomes and the socioeconomic status of patients’ families, using a targetable measure of socioeconomic status termed material hardship. They also plan to conduct interviews with family members to identify factors that possibly influence patient outcomes, with the anticipation of developing targeted interventions.
Reference
Bona K, Blonquist TM, Neuberg DS, Silverman LB, Wolfe J. Impact of socioeconomic status on timing of relapse and overall survival for children treated on Dana-Farber Cancer Institute ALL Consortium Protocols (2000—2010) [published online February 23, 2016]. Pediatr Blood Cancer. doi:10.1002/pbc.25928.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More